articleTop 1% cited
Efavirenz plasma levels can predict treatment failure and central nervous system side effects in HIV-1-infected patients
AIDS · 2001 · Vol. 15(1) · pp. 71–75
Catia MarzoliniAmalio Telenti(University Hospital of Lausanne)Laurent A. DécosterdGilbert Greub(University Hospital of Lausanne)Jérôme BiollazThierry Buclin✉(GTx (United States))
Abstract
Treatment failure and CNS side-effects are associated with low and high efavirenz plasma levels, respectively. The important inter-individual variability in efavirenz levels strongly argues for dose adjustment on the basis of therapeutic drug monitoring to optimize treatment.
HIV/AIDS drug development and treatmentHIV Research and TreatmentHIV/AIDS Research and InterventionsEfavirenzReverse-transcriptase inhibitorTolerabilityTherapeutic drug monitoringMedicinePharmacokineticsInternal medicineDrugPharmacologyViral load
MeSH terms
AdultAgedAlkynesCentral Nervous SystemCyclopropanesDrug Therapy, CombinationFemaleHumansMaleMiddle AgedOxazinesPredictive Value of TestsHIV-1HIV InfectionsTreatment Failure
Funding
- Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung
Citations
832
FWCI
21.56
field-weighted impact
References
12
Percentile
100%
vs. same field & year
Citations per year
Cited by
The Cytochrome P450 2B6 (CYP2B6) Is the Main Catalyst of Efavirenz Primary and Secondary Metabolism: Implication for HIV/AIDS Therapy and Utility of Efavirenz as a Substrate Marker of CYP2B6 Catalytic Activity
Journal of Pharmacology and Experimental Therapeutics · 2003 · 591 citations
Related articles
Citation Network
How this paper connects to the literature. Drag to explore, click any node to open that paper.